Author: jeremy

April 8, 2019 – April 8, 2019 – FACIT is pleased to announce recent successes in its mission to help bridge the capital gap often experienced by early-stage entrepreneurs.

April 2, 2019 – April 2, 2019 – Ontario First investor FACIT congratulates portfolio company Fusion Pharmaceuticals, a clinical-stage biotech developing novel targeted alpha radiotherapies

April 1, 2019 – April 1, 2019 – Triphase Accelerator has dosed their first patient in a Phase 1 clinical trial of TRPH-222, an anti-CD22 antibody-drug conjugate (ADC) for the treatment of patients with lymphoma.

February 25, 2019 – Fusion Pharma announced the first patient dosing with lead candidate in Phase 1 trial for solid tumors.

February 6, 2019 – “For innovation, open science means open for business”, February 6, 2019

January 29, 2019 – “U.S. biotech giant Celgene invests in Ontario-developed blood-cancer drug in potential $1-billion deal”, January 29, 2019

January 29, 2019 – Triphase Accelerator, together with its majority shareholder FACIT, today announced a new strategic collaboration with Celgene for a first-in-class preclinical therapeutic targeting the WDR5 protein for the treatment of blood cancers including leukemia.

January 10, 2019 – FACIT’s Compass Rose Oncology Fund is providing the follow-on investment. DNAstack also previously received capital from FACIT’s early-stage Prospects Oncology Fund, illustrating FACIT’s strategy to ensure promising companies grow roots and scale up in Ontario.

November 12, 2018 – KA Imaging, a recent Prospects Fund recipient, is partnering with Grand River Hospital to conduct a pilot study on the use of a high-resolution multi-energy digital x-ray imager for patients with lung nodules.

October 11, 2018 – Both leaders are passionate supporters of the Ontario life science sector, have broad industry experience and decades of work with entrepreneurial ventures.